Summary & Overview
HCPCS J1572: Intravenous Immune Globulin (Flebogamma) 500 mg
HCPCS Level II code J1572 represents a 500 mg vial of intravenous immune globulin (flebogamma/flebogamma dif), packaged as a non-lyophilized (liquid) formulation. Nationally, immune globulin therapies are clinically important for treating immune deficiencies, autoimmune and inflammatory disorders, and certain acute conditions; accurate coding for product, dosing, and site of service drives billing, inventory tracking, and clinical documentation.
This publication analyzes coverage and billing considerations for major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, common service settings, and benchmark metrics where available. The report summarizes clinical context for intravenous immune globulin use, highlights typical sites of administration (hospital outpatient and ambulatory infusion centers), and outlines where data was not available in the input.
The piece is designed to help revenue integrity, clinical billing teams, and policy analysts understand how HCPCS Level II code J1572 is used in practice, what payers commonly cover, and what types of operational and documentation elements are most relevant. Data not available in the input is noted when applicable; the main focus remains on the clinical description, service type, and national payer coverage landscape.
Billing Code Overview
HCPCS Level II code J1572 describes an intravenous injection of immune globulin (flebogamma/flebogamma dif), non-lyophilized (liquid), 500 mg. This code represents the drug product and dosage unit used when administering immune globulin intravenously.
Service Type: Intravenous immune globulin infusion (medication administration)
Typical Site of Service: Hospital outpatient infusion center, ambulatory infusion center, or clinic setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 56-year-old patient with primary immunodeficiency presents to an outpatient infusion center for scheduled intravenous immune globulin replacement therapy. The patient has a prescription for intravenous immune globulin, supplied as a liquid formulation (e.g., Flebogamma DIF), dosed to deliver multiple grams per infusion; billing is per 500 mg unit using J1572. The clinical workflow begins with nursing triage and vital signs, verification of the medication order and dose by the infusion pharmacist, venous access placement or use of existing port, pre-medication assessment (antipyretic or antihistamine as indicated), and administration of the infusion under nursing supervision with rate escalation per protocol. Monitoring includes vital signs at baseline and periodically during the infusion, documentation of any infusion-related reactions, and post-infusion observation for delayed adverse events. The encounter may occur in an outpatient hospital infusion suite, freestanding infusion center, or physician office with appropriate emergency support available. Documentation includes the signed medication administration record, lot number and vial count, indication tied to an ICD-10 diagnosis, and any applicable modifier usage for billing nuances (e.g., JG for multiple payer reporting, QX for rendering clinician eligibility when applicable).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|